Literature DB >> 15532781

Prognostic factors for hepatocellular carcinoma presenting with macroscopic portal vein tumor thrombus.

Haruhito Sakata1, Masaru Konishi, Munemasa Ryu, Taira Kinoshita, Mitsuo Satake, Noriyuki Moriyama, Takenori Ochiai.   

Abstract

BACKGROUND/AIMS: This study examines the prognostic factors including radiological findings of hepatocellular carcinoma presenting with macroscopic portal vein tumor thrombus.
METHODOLOGY: From September 1992 to December 2002, 107 patients with hepatocellular carcinoma and a macroscopic portal vein tumor thrombus were treated at the National Cancer Center Hospital East. Patients' characteristics and diagnostic findings of computed tomography, angiography and computed tomography angiography were analyzed to determine the factors significantly related to the patients' prognosis.
RESULTS: Enhanced portal vein tumor thrombus, main tumor occupying over 40% of the liver and distribution of tumors significantly affected survival. Cavernous transformation, thread and streak signs, arterio-portal shunt, extent of tumor thrombus, grade of venous invasion and tumor size did not affect survival. Clinical findings showed that Child-Pugh classification score over 7, etiology of hepatitis, total bilirubin over 2.2 mg/dL, prothrombin time under 50% and liver transaminases over 100 IU/L were poor prognostic factors. Multivariate analysis showed that AST over 100 IU/L, viral hepatitis and tumor occupying over 40% of the liver strongly affected the prognosis.
CONCLUSIONS: Based on the present results, the most strongly affected prognostic factor was liver function as indicated by high level of transaminases. Various radiological findings did not affect survival. The elevation of transaminases seemed due to destruction of hepatocytes by growing tumor and circulatory disruption due to portal vein tumor thrombus. We concluded that radiological findings of hepatocellular carcinoma presenting with portal vein tumor thrombus indicated only intrahepatic status but not survival. First treatment for hepatocellular carcinoma presenting with portal vein tumor thrombus should be to improve the liver function. Treatment against hepatitis virus might be important and patients with AST over 100 IU/L and a tumor occupying over 40% should not undergo surgical resection.

Entities:  

Mesh:

Year:  2004        PMID: 15532781

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

1.  Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Keiko Takano; Nami Imai; Chisato Saeki; Nao Fushiya; Yoshinari Miyakawa; Hirokazu Nishino; Hisao Tajiri
Journal:  Med Oncol       Date:  2012-03-30       Impact factor: 3.064

2.  Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study.

Authors:  Qing-he Tang; Ai-jun Li; Guang-ming Yang; Eric C H Lai; Wei-ping Zhou; Zhi-hao Jiang; Wan Yee Lau; Meng-chao Wu
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

3.  Highly metabolic thrombus of the portal vein: 18F fluorodeoxyglucose positron emission tomography/computer tomography demonstration and clinical significance in hepatocellular carcinoma.

Authors:  Long Sun; Yong-Song Guan; Wei-Ming Pan; Gui-Bing Chen; Zuo-Ming Luo; Ji-Hong Wei; Hua Wu
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

4.  Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival.

Authors:  Chi-Sin Changchien; Chao-Long Chen; Yi-Hao Yen; Jing-Houng Wang; Tsung-Hui Hu; Chuan-Mo Lee; Chih-Chi Wang; Yu-Fan Cheng; Yu-Jie Huang; Chih-Yun Lin; Sheng-Nan Lu
Journal:  J Gastroenterol       Date:  2008-02-29       Impact factor: 7.527

5.  Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.

Authors:  Xubiao Wei; Yabo Jiang; Xiuping Zhang; Shuang Feng; Bin Zhou; Xiaofei Ye; Hui Xing; Ying Xu; Jie Shi; Weixing Guo; Dong Zhou; Hui Zhang; Huichuan Sun; Cheng Huang; Congde Lu; Yaxin Zheng; Yan Meng; Bin Huang; Wenming Cong; Wan Yee Lau; Shuqun Cheng
Journal:  J Clin Oncol       Date:  2019-07-08       Impact factor: 44.544

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.